Clinical Trial Update: Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating whether tenofovir alafenamide reduces clinical events in chronic hepatitis B patients beyond current guideline indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Vemlidy (tenofovir alafenamide)

Snippet

Sponsor: Young-Suk Lim | Conditions: Chronic Hepatitis b | Phase 4 | Status: ACTIVE_NOT_RECRUITING